[ALNY] Alnylam Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 41.29 Change: 1.9 (4.82%)
Ext. hours: Change: 0 (0%)

chart ALNY

Refresh chart

Description: Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-CC5 for the treatment of complement-mediated diseases; ALN-AS1 for the treatment of hepatic porphyrias; ALN-PCS for the treatment of hypercholesterolemia; ALN-AAT for the treatment of AAT deficiency liver disease; ALN-TMP for the treatment of beta-thalassemia and iron-overload disorders; ALN-ANG for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia; and other programs. The company?s partner-based product development clinical and pre-clinical programs comprise ALN-RSV01 for the treatment of respiratory syncytial virus infection; ALN-VSP for the treatment of liver

Fundamental Ratios
Shares Outstanding EPS-4.83 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 154.11% Sales Growth - Q/Q-22.82% P/E-15.75
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-9.84% ROE-10.71% ROI
Current Ratio13.51 Quick Ratio Long Term Debt/Equity Debt Ratio0.05
Gross Margin Operating Margin-309.32% Net Profit Margin-263.44% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities598.98 M Cash From Investing Activities-341.33 M Cash From Operating Activities-26.25 M Gross Profit
Net Profit-50.78 M Operating Profit-52.22 M Total Assets1.63 B Total Current Assets1.09 B
Total Current Liabilities80.69 M Total Debt Total Liabilities132.28 M Total Revenue18.54 M
Technical Data
High 52 week148.54 Low 52 week65.07 Last close73.34 Last change0.91%
RSI28.58 Average true range5.13 Beta1.23 Volume734.61 K
Simple moving average 20 days-3.14% Simple moving average 50 days-10.23% Simple moving average 200 days-27.17%
Performance Data
Performance Week5.72% Performance Month0.47% Performance Quart-24.29% Performance Half-26.65%
Performance Year-44.58% Performance Year-to-date-42.27% Volatility daily4.85% Volatility weekly10.84%
Volatility monthly22.22% Volatility yearly76.97% Relative Volume208.92% Average Volume940.78 K
New High New Low


2019-08-15 09:00:38 | BioBoyScout’s Online Biotech Valuation Calculators Help Small Investors See Value in Arrowhead Pharmaceuticals ARWR

2019-08-15 08:28:12 | Regeneron Gets FDA Nod for Eylea Injection Prefilled Syringe

2019-08-14 09:21:01 | Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More

2019-08-14 08:00:00 | Alnylam to Report New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias

2019-08-13 07:30:00 | Alnylam Pharmaceuticals and Ironwood Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria AHP

2019-08-13 07:30:00 | Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria AHP

2019-08-12 16:13:00 | Alnylam Adds on Sales, Looks to Pipeline for Further Growth

2019-08-07 16:04:31 | Edited Transcript of ALNY earnings conference call or presentation 6-Aug-19 12:00pm GMT

2019-08-07 08:13:12 | Alnylam's ALNY Q2 Earnings and Revenues Miss Estimates

2019-08-06 15:23:36 | Alnylam Pharmaceuticals Inc ALNY Q2 2019 Earnings Call Transcript

2019-08-06 13:09:05 | Regeneron REGN Q2 Earnings Top Estimates, Eylea Sales Solid

2019-08-06 08:55:12 | Alnylam Pharmaceuticals ALNY Reports Q2 Loss, Lags Revenue Estimates

2019-08-06 07:30:00 | Alnylam Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Period Activity

2019-08-06 07:22:08 | The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering

2019-08-05 16:00:00 | Alnylam Announces U.S. Food and Drug Administration FDA Granted Priority Review of the Givosiran New Drug Application NDA for the Treatment of Acute Hepatic Porphyria

2019-08-02 11:12:03 | bluebird's BLUE Loss Wider Than Expected, Revenues Beat

2019-08-02 10:28:02 | Ultragenyx RARE Reports Wider-Than-Expected Loss in Q2

2019-08-01 09:54:01 | Amgen AMGN Catches Eye: Stock Jumps 5.7%

2019-07-30 10:38:02 | Earnings Preview: Alnylam Pharmaceuticals ALNY Q2 Earnings Expected to Decline

2019-07-29 10:08:10 | A Look At The Fair Value Of Alnylam Pharmaceuticals, Inc. NASDAQ:ALNY

2019-07-26 10:38:02 | Alkermes ALKS Earnings and Sales Beat Estimates in Q2

2019-07-25 11:25:03 | Medicines Company MDCO Q2 Earnings Top, Inclisiran in View

2019-07-24 13:54:05 | Alexion ALXN Q2 Earnings Beat Estimates, Guidance Raised

2019-07-23 16:00:00 | Alnylam to Webcast Conference Call Discussing Second Quarter 2019 Financial Results

2019-07-23 07:00:00 | Alnylam Launches ONPATTRO® patisiran for the Treatment of Polyneuropathy in hATTR Amyloidosis, the First-Ever RNAi Therapeutic Approved in Canada

2019-07-19 09:41:01 | Horizon's NDA for Procysbi New Dosage Form Accepted by FDA

2019-07-16 07:00:00 | Alnylam and 23andMe Collaborate on +MyFamily Program to Increase Awareness of TTR-Related Hereditary Amyloidosis

2019-07-11 09:05:01 | Horizon Therapeutics Files BLA to FDA for Eye Disease Drug

2019-07-11 08:58:12 | Adverum ADVM Jumps: Stock Rises 5.1%

2019-07-11 08:30:00 | Alnylam Pharmaceuticals Announces Transition of Chief Financial Officer

2019-07-10 17:53:09 | Mirati Inks Deal with Novartis to Evaluate Tumor Candidate

2019-07-10 17:51:09 | Kadmon Initiates Dosing in Study for Systemic Sclerosis Drug

2019-07-05 12:04:04 | Catalyst Pharma Focuses on Firdapse Launch & Label Expansion

2019-07-04 09:00:01 | Alnylam ALNY Upgraded to Strong Buy: What Does It Mean for the Stock?

2019-07-02 16:01:00 | Arbutus Sells Part of its ONPATTRO™ patisiran Royalty Interest to OMERS

2019-07-02 14:57:06 | Alnylam Submits MAA in Europe for RNAi Therapeutic Givosiran

2019-07-01 11:00:03 | Regeneron/Sanofi's Dupixent Gets Positive CHMP Recommendation

2019-07-01 07:00:00 | Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Givosiran for the Treatment of Acute Hepatic Porphyria

2019-06-27 07:39:11 | Regeneron & Sanofi Get FDA Nod for Dupixent Label Expansion

2019-06-25 08:00:12 | Alnylam Presents New Data for RNAi Therapeutic Onpattro

2019-06-24 07:00:00 | Alnylam Presents New ONPATTRO® patisiran Results at the 2019 Peripheral Nerve Society Annual Meeting

2019-06-21 07:00:00 | Alnylam Announces Progress with RNAi Therapeutics Platform, Including Oral Route of Administration and CNS and Ocular Delivery

2019-06-19 20:09:56 | Here’s What Hedge Funds Think About Alnylam Pharmaceuticals, Inc. ALNY

2019-06-18 09:58:01 | Alnylam Completes Enrollment in Phase III Study of Lumasiran

2019-06-18 08:00:00 | Alnylam Announces Approval in Japan of ONPATTRO® for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy

2019-06-17 09:12:01 | Regeneron REGN Presents Positive Data on Lymphoma Candidate

2019-06-17 07:00:00 | Alnylam Completes Enrollment for ILLUMINATE-A Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 PH1

2019-06-14 14:50:50 | Why Alnylam Pharmaceuticals, Inc. NASDAQ:ALNY Is A Financially Healthy Company

2019-06-13 12:03:21 | Boston-area biopharm firm has big plans in Philadelphia

2019-06-13 08:06:45 | See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.